Detalles de la búsqueda
1.
Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Patients With Cushing Syndrome, Does Not Cause Prolongation of the Cardiac QT Interval.
Endocr Pract
; 30(1): 11-18, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37805100
2.
Human pharmacokinetics prediction with an in vitro-in vivo correction factor approach and in vitro drug-drug interaction profile of bictegravir, a potent integrase-strand transfer inhibitor component in approved biktarvy® for the treatment of HIV-1 infection.
Xenobiotica
; 52(12): 1020-1030, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36701274
3.
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Lancet
; 390(10107): 2063-2072, 2017 Nov 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28867497
4.
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Lancet
; 390(10107): 2073-2082, 2017 Nov 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28867499
5.
Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment.
Antimicrob Agents Chemother
; 60(9): 5135-40, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27216057
6.
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Lancet
; 385(9987): 2606-15, 2015 Jun 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-25890673
7.
Pharmacokinetics and safety of boosted elvitegravir in subjects with hepatic impairment.
Antimicrob Agents Chemother
; 58(5): 2564-9, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24550332
8.
Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairment.
HIV Clin Trials
; 15(6): 269-73, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25433666
9.
Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial.
AIDS Res Ther
; 11: 39, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25926858
10.
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.
J Clin Oncol
; 41(30): 4779-4789, 2023 10 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37364223
11.
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors.
Clin Cancer Res
; 28(15): 3214-3224, 2022 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35583817
12.
An In Vitro and In Vivo Evaluation of the Effect of Relacorilant on the Activity of Cytochrome P450 Drug Metabolizing Enzymes.
J Clin Pharmacol
; 61(2): 244-253, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32869328
13.
Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption.
Adv Drug Deliv Rev
; 60(6): 717-33, 2008 Mar 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-18199522
14.
Quantitation of intracellular triphosphate metabolites of antiretroviral agents in peripheral blood mononuclear cells (PBMCs) and corresponding cell count determinations: review of current methods and challenges.
Expert Opin Drug Metab Toxicol
; 14(8): 781-802, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-30010446
15.
Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals.
J Acquir Immune Defic Syndr
; 78(4): 465-472, 2018 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29649076
16.
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Lancet HIV
; 5(7): e357-e365, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29925489
17.
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.
Lancet HIV
; 5(7): e347-e356, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29925490
18.
ITC Commentary on Metformin Clinical Drug-Drug Interaction Study Design That Enables an Efficacy- and Safety-Based Dose Adjustment Decision.
Clin Pharmacol Ther
; 104(5): 781-784, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29761830
19.
Gab3, a new DOS/Gab family member, facilitates macrophage differentiation.
Mol Cell Biol
; 22(1): 231-44, 2002 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-11739737
20.
Gab3-deficient mice exhibit normal development and hematopoiesis and are immunocompetent.
Mol Cell Biol
; 23(7): 2415-24, 2003 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-12640125